Reslizumab, another IL-5-blocking agent, was able to reduce the glucocorticoid dose in the therapy of EGPA patients, while it had a promising impact on outcomes of recipients (46). This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.